Sagimet Biosciences Files 8-K Report

Ticker: SGMT · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1400118

Sentiment: neutral

Topics: 8-K, disclosure, corporate-filing

TL;DR

Sagimet Biosciences filed an 8-K on 12/18/25 covering disclosures and exhibits.

AI Summary

On December 18, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as 3-V Biosciences, Inc., is headquartered in San Mateo, California.

Why It Matters

This 8-K filing provides an update on Sagimet Biosciences' corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing serves as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported is dated December 18, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Sagimet Biosciences Inc.

Where are Sagimet Biosciences Inc.'s principal executive offices located?

The principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.

What was Sagimet Biosciences Inc. formerly known as?

Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc.

Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-12-18 07:05:52

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 18, 2025, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 furnished herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. On December 18, 2025, the Company issued a press release announcing positive results in the Phase 1 pharmacokinetic trial of a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, and a thyroid hormone receptor beta agonist, resmetirom. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference .

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated December 18, 2025 99.2 Press Release of Sagimet Biosciences Inc., dated December 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: December 18, 2025 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing